**Core tip:** Peptide vaccines are a promising tool for colorectal cancer (CRC) treatment. Direct comparison of tumor-associated antigens (TAAs) and neoantigens reveals clear superiority of the latter for several reasons. TAAs, albeit easier to identify and even shared by many patients, did not prove effective in clinical trials. Additionally, and due to their unspecificity, they frequently trigger severe adverse events. This risk is neglectable for tumor-specific neoantigens - thus compensating for the costly and laborious identification of such antigens expressed in individual patient tumors. Intelligent modern CRC vaccines will likely combine several or even many individual neoantigen-derived peptides with immuno-chemotherapy, adjuvants or further immuno-modulators.

INTRODUCTION
============

Therapy of colorectal carcinoma (CRC) has been improved over the years with advanced surgical and chemotherapeutic procedures but challenges in sight of efficiency and adverse effects must still be accomplished. Especially late stage CRC patients still have a relatively poor prognosis. Only recently, immunotherapy has reached general clinical acceptance with the break-through results of immune checkpoint inhibition for selected cancer types or subgroups - also for CRC.

One approach further improving this type of CRC therapy is the vaccination with peptides alone, peptide-expressing viruses, peptide-loaded antigen presenting cells or application of peptide-specific T cells. Historically, the development of such cancer vaccines started with peptides derived from tumor-associated antigens (TAAs).

TAAs
====

TAAs are proteins that are significantly over-expressed in cancer compared to normal cells and are therefore also abundantly presented on the cancer cell's surface. Peptides of these TAAs bound to human leukocyte antigen (HLA) can be recognized by T cells initiating an anti-cancer immune response (Figure [1](#F1){ref-type="fig"}). Therefore, these TAAs have been used as target structures for the development of cancer vaccines (see Table [1](#T1){ref-type="table"} for an overview of CRC focused clinical studies).

###### 

Clinical vaccination trials focused on colorectal cancer patients

  **Target type**   **Target molecule**                                                          **Vaccination strategy**                                                                                                 **Therapy**      **No. of CRC Patients**   **Clinical response**                    **Ref**.
  ----------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------- ------------------------- ---------------------------------------- ----------
  TAA               CEA                                                                          Altered peptide loaded on DC                                                                                                              10/12                     2 CR, 2 SD, 1 MR, 7 PD                   \[8\]
  TAA               CEA                                                                          CEA peptides pulsed DC                                                                                                                    10                        2 SD, 8 PD                               \[9\]
  TAA               CEA                                                                          CEA peptides pulsed DC                                                                                                                    10                        7 had CTL increase                       \[10\]
  TAA               MAGE                                                                         MAGE-A-pulsed DC                                                                                                                          21                        21 PD                                    \[15\]
  TAA               MAGE                                                                         synthesized helper/killer-hybrid epitope long peptide (H/K-HELP) of MAGE-A4                                                               1                         SD                                       \[14\]
  TAA               MUC1                                                                         MUC1-mannan fusion protein                                                                                               Chemo- therapy   18                        2 SD, 16 PD                              \[17\]
  TAA               MUC1                                                                         100-amino acid synthetic MUC1 peptide with Poly-ICLC                                                                                      39                        20 responders (IgG), 19 non-responders   \[18\]
  TAA               MUC1                                                                         irradiated allogeneic colorectal carcinoma cell lines with GM-CSF-producing bystander cell line (K562)                                    9                         4 CR, 5 PD                               \[19\]
  TAA               Survivin                                                                     survivin-2B peptide                                                                                                                       15                        1 MR, 3 SD, 11 PD                        \[21\]
  TAA               WT1                                                                          HLA-A or HLA-DR restricted peptides on DCs                                                                               Chemo- therapy   3                         3 SD                                     \[22\]
  TAA               RNF43, TOMM34                                                                peptides,with Montanide ISA 51                                                                                           Chemo- therapy   21                        16 SD                                    \[29\]
  TAA               RNF43, TOMM34                                                                HLA-A\*2402-restricted peptides                                                                                          Chemo- therapy   22                        13 CTL induction                         \[31\]
  TAA               RNF43, TOMM34                                                                Peptides with Montanide ISA 51                                                                                                            24                        6 SD, 18 PD                              \[30\]
  TAA + VEGFR       RNF43, TOMM34, FOXM1, MELK, HJURP, VEGFR-1, VEGFR-2                          HLA-A2402- restricted peptides with Montanide ISA 51                                                                     Chemo- therapy   30                        3 PR, 15 SD, 12 PD                       \[32\]
  TAA + VEGFR       RNF43, TOMM34, KOC1, VEGFR-1, VEGFR-2                                        HLA-A\*2402-restricted peptides with Montanide ISA 51                                                                                     19                        1 CR, 6 SD, 12 PD                        \[33\]
  PPV TAA           cypB, Ick, SART 1-3, ART4                                                    2-4 HLA-A24-restricted Peptides matching to patient's pre-vaccination immune response with Montanide ISA 51                               10                        1 PR, 1 SD, 8 PD                         \[34\]
  PPV TAA           SART3, Lck, WHS, HNR, MRP3, PAP, EZH2, CEA, PSCA, UBE, Her2/neu, PSA, CypB   2-4 HLA-A24- or HLA-A2 restricted Peptides matching to patient's pre-vaccination immune response with Montanide ISA 51   Chemo- therapy   7                         1 SD, 6 PD                               \[35\]
  PPV TAA           SART2-3, Lck, MRP3, EIF4EBP, WHSC2, CypB, CEA, UBE, Her2/neu,                2-4 HLA-A24- or HLA-A2 restricted Peptides matching to patient's pre-vaccination immune response with Montanide ISA 51   Chemo- therapy   14                        3 MR, 3 SD, 8 PD                         \[36\]
  Neoantigen        AIM2(-1), HT001(-1), TAF1B(-1)                                               Frameshift peptides with Montanide ISA 51                                                                                                 22                        16 immune response (CTL/IgG induction)   \[52\]
  Neoantigen        KRAS                                                                         13-mer ras peptide with Detox adjuvant                                                                                                    10                        1 SD, 2 cytotoxic activity               \[62\]
  Neoantigen        KRAS                                                                         13-mer ras peptide with Detox adjuvant                                                                                                    7                         4 remained with no evidence of disease   \[64\]
  Neoantigen        KRAS                                                                         13-mer ras peptide with Il-2 or GM-CSF or both                                                                                            38                        4 SD, 34 PD                              \[66\]

CRC: Colorectal cancer; CR: Complete response; CTL: Cytotoxic T lymphocyte; DC: Dendritic cell; GM-CSF: Granulocyte macrophage colony-stimulating factor; HLA: Human leukocyte antigen; MR: Minor response; PD: Progressive disease; PR: Partial response; SD: Stable disease; CEA: Carcinoembryonic antigen; TAA: Tumor-associated antigen.

![Comparison of tumor-associated antigens and tumor-specific antigens properties. The figure depicts properties and processing steps of antigens which are either tumor associated (TAA; blue; left side) or tumor specific (TSA; pink; right side). The course until antigen processing includes the following steps: transcription of genomic locus (TAA, blue) or mutation containing locus (TSA; pink), translation and RNA processing, protein degradation and MHC molecule loading and finally presentation of the antigen (TAA or TSA) on the cell surface embedded in MHC molecules. TAA-proteins are expressed to a high level in the tumor and to a low level in other organs and tissues (blue sprinkled patient). The neo-antigenic part of the TSA-protein is solely expressed in the tumor (pink sprinkled tumor). Recognition of the tumor cell by T cells (Tc, *e.g*., CTL) takes place *via* the T cell receptor (TCR; green). The avidity is increased for TSAs (indicated by the "speedlines" on the right side of the Tc). The tumor may counteract the immune recognition by expression of immune checkpoint molecules such as PD-L1 (orange). This occurs to a much higher extent in TSA baring than in merely TAA baring tumors. The middle panel indicates the degree of T cell avidity (first bar), extent of immunogenicity/T cell specificity (second bar), level of immune escape / checkpoint expression (third bar), shared antigen character (fourth bar), risk of side effects (fifth bar) and cost-labor efficacy (sixth bar) ranging from low (red) to high (green). APM: Antigen-presenting machinery; TAA: Tumor-associated antigens; TCR: T cell receptor; TSA: Tumor-specific antigen.](WJG-24-5418-g001){#F1}

Carcinoembryonic antigen
------------------------

One of the first TAAs ever identified was the carcinoembryonic antigen (CEA) which is also overexpressed in CRC\[[@B1]\]. In initial *in vitro* experiments, it could be proven that CEA-derived peptide-loaded dendritic cells (DCs) are able to induce CEA-specific cytotoxic T lymphocyte (CTL) activity\[[@B2]\]. However, a CEA-derived peptide with low avidity led to an inefficient immune response lacking activated CTLs\[[@B3]\]. The explanation for such inefficient T cell activation lies in the fact that TAAs like CEA are not really cancer specific but are also expressed by normal epithelial cells. Therefore, the organism must, for the most part, be tolerant to such TAAs in order to prevent autoimmunity.

Consequently, different approaches for modifying CEA vaccines were developed to overcome or weaken this immune tolerance. Using an altered peptide ligand of CEA with higher HLA binding affinity could efficiently activate specific CTLs *in vitro*\[[@B4]\]. Another way to enhance specific T cell activation was the development of DNA vaccines encoding the CEA-derived peptide(s) together with sequences for stimulating cytokines, adjuvants or supportive T helper cell epitopes. In murine models, this kind of vaccine showed higher T cell activation in comparison to peptide-only vaccines\[[@B5],[@B6]\]. However, in clinical trials, the efficacy of CEA peptide vaccines was overall not satisfying, clinical response rate did not exceed 17 %\[[@B7]-[@B10]\].

Melanoma associated antigen
---------------------------

The melanoma associated antigen (MAGE), first discovered in melanomas, belongs to the group of cancer/testis antigens. This subgroup of TAAs is expressed only in testis and cancer cells. MAGE has subsequently been found to be expressed in the majority of adenocarcinomas. The rate of CRCs identified as being MAGE-positive strongly varied between different studies and MAGE variants: 14 % for MAGE-A\[[@B11]\], 51 % for MAGE-A1-6\[[@B12]\] and 28 % for MAGE-A3\[[@B13]\].

A clinical benefit by a MAGE-directed vaccination therapy could be shown in a case study by Takahashi et al\[[@B14]\]. They reported that a synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 is able to induce an orchestrated CD4^+^ and CD8^+^ immune response leading to a slightly decreased tumor growth and resulting in stable disease. In a vaccination study investigating different TAAs, an increase in specific CTLs could be detected but clinical response was not observed\[[@B15]\].

Other TAAs
----------

Progress in CRC vaccine development was made also with a variety of other TAAs. A peptide vaccination consisting of two different 9-mers derived from MUC-1 combined with CpG oligonucleotides and granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvants reduced tumor burden in a MUC1.Tg mouse model. In the prophylactic setting, even a complete protection against a syngeneic colon cancer cell line was achieved and attributed to the MUC 1-specific activation of the immune system\[[@B16]\]. However, these promising results could not be proven in clinical trials. Although an increase in anti MUC1 IgGs could be detected, neither cellular nor clinical response was observed\[[@B17]-[@B19]\].

CRC patients treated with survivin-derived peptide-pulsed DCs showed an increased number of specific CTLs\[[@B20],[@B21]\]. In a minority of patients, also a drop in level of tumor markers and even in total tumor volume was witnessed\[[@B21]\].

Furthermore, success was achieved in CRC-focused studies on vaccination with peptides obtained from Wilms tumor 1 protein\[[@B22]\], transmembrane 4 superfamily member 5 protein\[[@B23]\], mitotic centromere associated kinesin\[[@B24]\] and epidermal growth factor receptor\[[@B25]\].

Of note and in contrast to other tumor entities, NY-ESO-1 is not overexpressed in CRC\[[@B11],[@B26],[@B27]\] and has therefore not been exploited as a target for immunotherapy.

COMBINATION OF TAAs
===================

Single peptide vaccines often showed a significant immune response which was, however, not accompanied by a significant reduction of tumor burden. Thus, subsequent vaccination studies included more than one TAA-derived peptide to ameliorate clinical response.

After the identification of the ring finger protein 43 (RNF43) as a CTL-inducing peptide\[[@B28]\], it was often investigated in combination with other peptides. At first Okuno et al\[[@B29]\] combined chemotherapy with a RNF43 and a 34-kDa translocase of the outer mitochondrial membrane (TOMM34) peptide in a phase I clinical trial which resulted in 83 % stable disease and a mean survival time of 24 mo, but no reduction in tumor burden was observed. The efficiency of inducing specific CTLs by RNF43 and TOMM34 was also proven by additional studies\[[@B30],[@B31]\].

To further improve clinical response, Okuno et al\[[@B32]\] tested a seven peptide vaccine containing peptides from RNF43, TOMM34, forkhead box M1, maternal embryonic leucine zipper-kinase, holliday junction recognizing-protein and vascular endothelial growth factor receptor 1 and 2 (VEGFR-1 and VEGFR-2). In 9 out of 30 vaccinated patients, a CTL response to all 7 peptides could be detected including two of the three partial responders of the study. Moreover, there was a correlation between the number of vaccine peptide-specific CTL responses and overall survival\[[@B32]\]. Similar results were observed in a vaccination study with peptides from RNF43, TOMM34, VEGFR-1 and VEGFR-2 as well as insulin-like growth factor-II mRNA binding protein 3\[[@B33]\].

PERSONALIZED PEPTIDE VACCINES
=============================

To further enhance the efficiency of cancer vaccines, the next wave of trials focused on personalized peptide vaccines. This personalization was achieved by measuring existing peptide-specific CTL precursors in the patients' blood, as well as screening for peptide-specific IgGs, followed by vaccination with CTL-reactive peptides.

In a phase I clinical trial, Sato et al\[[@B34]\] treated 10 CRC patients with 2-4 matching peptides derived from cytochrom B, intestinal cell kinase, squamous cell carcinoma antigen recognized by T cells (SART)1-3 and ADP-ribosyltransferase 4. Peptide specific CTLs increased in 50 % of patients, peptide specific IgGs in 60 %. In half of the patients an elevated functional CTL activity was observed in cytotoxicity assays. In spite of this enhanced immune response, only two patients could clinically benefit from vaccination and had a partial response (reduction of metastasis' volume) and a stable disease, respectively.

In a subsequent study, the effect of a personalized peptide vaccine in combination with a 5-fluorouracil derivative was investigated\[[@B35]\]. After six vaccinations, six out of seven patients responded to at least one peptide with increased CTL and IgG levels. But only one patient showed stable disease. He responded to peptides derived from SART3, Tyrosine-protein kinase Lck and Wolf-Hirschhorn syndrome protein.

The combination of personalized peptide vaccination and chemotherapy resulting in clinical benefit was also proven in a further study. Hattori et al. vaccinated 14 metastatic CRC patients with up to four personal HLA-matched peptides. This was combined with a 5-fluoruracil based standard chemotherapy\[[@B36]\]. Although neither partial nor complete responses were obtained, three patients showed minor response, defined as a reduction in tumor size. Furthermore, three additional patients had stable disease. The strongest immune responses were induced by peptides derived from SART2/3, multidrug resistance-associated protein 3, Her2/neu, cytochrome B, ubiquitin-conjugating enzyme E2 and CEA.

Besides, it could be proven that the number of peptides with increased CTL responses after vaccination was also significantly predictive of favorable overall survival\[[@B37]\] similar to the correlation found in studies with combinations of TAA vaccines\[[@B32]\].

NEOANTIGENS - TRULY TUMOR-SPECIFIC ANTIGENS
===========================================

The stepwise acquisition and accumulation of mutations has been generally recognized as major mechanism for cancer initiation and progression. It not only leads to enhanced or reduced expression of genes but also to the expression of sequence-modified proteins - the so-called neoantigens (see Figure [1](#F1){ref-type="fig"}). Hence, the probability of creating neoantigens is rising simply with the number of mutations present in a given cancer cell\[[@B38]\]. But the mutational burden and therefore the potential of expressing neoantigens varies clearly between different cancer entities. The highest somatic mutation frequency of around 10 mutations per megabase is found in cancers of the skin, lung and colorectum resulting in the expression of approximately 150 nonsynonymous mutations within expressed genes\[[@B39]\].

A hyper-mutational burden is caused by a deficiency in the mismatch repair system. This leads to replication errors especially in regions with repetitive nucleotides which are found in coding microsatellites. A mismatch repair deficient tumor shows microsatellite instability (MSI) with a huge variety of mutations. A similar or even still higher mutational burden can be caused by a mutation in the catalytic subunit of DNA polymerase epsilon (POLE) leading to hypermutation independent of MSI.

Because high neoantigen load of CRC has repeatedly been correlated with improved patient survival\[[@B40],[@B41]\], neoantigens have only recently been accepted as ideal targets for successful immunotherapy. In addition, as neoantigens are truly tumor-specific antigens (TSA) only presented by cancer cells but not by normal cells, the immune system can easily distinguish between malignant and healthy tissue - minimizing the risk of vaccination-induced severe adverse events (SAEs).

TGFΒRII and other frameshift mutations
--------------------------------------

Studies focused on single nucleotide insertions or deletions in coding microsatellites and identified several proteins frequently affected by frameshift mutations in MSI^high^ CRCs. Early a short form of the transforming growth factor beta receptor 2 (TGFβRII) was identified as such a frameshifted and therefore truncated protein with a role in tumor progression.

It could be proven that a 23-mer peptide derived from frameshift mutated TGFβRII is able to induce T cell proliferation predominantly in CD4^+^ T (helper) cells\[[@B42]\]. This promising result was confirmed by results from a frameshift mutated TGFβRII-derived 9-mer peptide\[[@B43]\]. But in contrast to the former study, the induced T cells were predominantly CD8^+^ and, more important, these activated T cells were able to lyse TGFβRII-mutated CRC cells in a HLA-restricted fashion.

TGFβRII-mutation-reactive T cells were also able to decrease tumor load in a mouse model and even significantly prolong survival\[[@B44]\] underlining the potential of frameshifted TGFβRII as immunotherapeutic target.

In further studies, it was proven that peptides derived from frameshifted caspase 5, mut-S homologue 3 and O-linked N-acetylglucosamine transferase gene are able to induce CTLs with cytotoxic activity against CRC cells\[[@B45]-[@B47]\]. In another approach, an antibody response directed against frameshifted homeobox protein CDX2 was detected in serum of a CRC patient\[[@B48]\].

There are several further candidate genes frequently presenting with frameshift mutations in coding microsatellites: PTHL3, HT001, AC1, ACVR2, SLC23A1, BAX, TCF-4 and MSH3\[[@B49]\]. In addition peptides derived from frameshift-mutated MARCKS-1, MARCKS-2, TAF1B‐1, PCNXL2-2, TCF7L2-2, Baxα+1\[[@B50]\] as well as CREBBP, AIM2, EP300 and TTK\[[@B51]\] have been suggested to be taken into consideration for developing cancer vaccines for MSI^high^ CRCs as auspicious experimental and bioinformatic data proved their importance.

In a first clinical trial, 22 CRC patients received vaccines containing peptides of frameshifted AIM2, HT001 and TAF1B\[[@B52]\]. No vaccine-related SAEs were observed and the induced immune response was significant: all patients responded to at least one of the peptides.

KRAS: an example of point mutated genes
---------------------------------------

In the process of cancer development mutations resulting in neoantigens can emerge in every coding region of the DNA. Neoantigens caused by KRAS are one example for point mutations in CRC. KRAS plays a major role in intracellular signaling cascades and is found mutated in more than 40 % of CRCs\[[@B53],[@B54]\]. Most frequent mutations are located at codon 12 (G12D or G12V mutation) or 13 (G13D mutation) of the *KRAS* gene and result in single amino acid substitutions in the expressed protein\[[@B55],[@B56]\]. Early approaches could prove that peptides derived from mutated KRAS can stimulate CTLs *in vitro*\[[@B57],[@B58]\] as well as in pancreatic\[[@B59],[@B60]\] and colorectal cancer\[[@B61]\]. A subsequent study also investigated the cytotoxic activity of mutated KRAS peptide-induced CTLs\[[@B62]\]. Only 2 of 10 CRC patients showed induction of peptide specific CD8^+^ but in addition, these cytotoxic T cells were able to lyse HLA-A2-positive target cells incubated with the 10-mer mutant peptide. Similar results were obtained in a xenograft study, where peptide-specific T cells were able to delay the growth of KRAS mutant pancreatic tumors\[[@B63]\].

In vaccination trials with peptides derived from mutated KRAS, clinical benefits for patients could be achieved. Although only two of seven CRC patients responded positive to a mutated KRAS peptide vaccination, four remained with no evidence of disease\[[@B64]\]. In a case report, one CRC patient was treated with activated T cells recognizing G12D KRAS\[[@B65]\]. After a single infusion, all seven lung metastases regressed for 9 mo until 1 metastatic lesion progressed.

To further enhance the immunological response in CRC patients, Rahma et al. combined the peptide vaccination of mutated KRAS with IL-2 or GM-CSF\[[@B66]\]. The strongest immune response could be detected in the group with GM-CSF as adjuvant; all CRC patients had an increase in interferon producing, specifically-activated T cells. Despite the high immune response rate, no patient showed clinical response and disease progressed in all cases. An increase in regulatory T cells, detectable in all CRC patients of this group, is a likely explanation for this negative result.

Other neoantigens
-----------------

Besides point and frameshift mutations there are further possibilities in creating neoantigens. Mutations at somatic splice sites as well as deregulated splicing factors can lead to alternative splice variants. A large-scale systematic investigation revealed that alternative splice variants in CRC are mainly caused by exon skipping, alternative promoter or terminator and intron retention\[[@B67]\]. A comparison between CRC and normal cells demonstrated that there are alternative splice variants exclusively expressed by cancer cells\[[@B68],[@B69]\]. That these altered peptides can be presented by HLA was already proven in a study focusing on melanoma\[[@B70]\]. Therefore, further investigation in this field of alternative splice variants could lead to an extended range of target structures for cancer vaccines.

Ditzel et al\[[@B71]\] found a completely different mechanism of neoantigen generation. They proved that the apoptotic markers cytokeratin 8 and 18 are only proteolytically truncated in CRC tissue but not in normal colon epithelia. The cancer-associated forms of cytokeratin 8 and 18 are early apoptosis markers and recognized by a human antibody specific for a heterotypic conformational epitope. However, this and similar epitopes can hardly serve as target structures for T cell-specific immunotherapies.

CHALLENGES FOR DEVELOPING A CRC VACCINE
=======================================

Genetic configuration and target selection
------------------------------------------

One important property for the development of a CRC vaccine is the genetic subtype of the patient. Around 15 % of CRCs are MSI^high^ and provide therefore a variety of mutations leading to neoantigens which are, as described above, often derived from frameshift mutations. Another form of hypermutated CRC is caused by POLE mutations - but only 3 % of CRC patients fit into this category. MSI^high^ or POLE mutations are responsible for a high mutational burden which is regularly correlated with increased lymphocyte infiltration into the tumors mirroring higher pre-vaccination antitumoral activity of the patients' immune system. Especially the intratumoral presence of CD8^+^ CD45RO^+^ T cells correlates with improved survival\[[@B72]\]. A CRC vaccine could further enhance or re-activate this anticancer activity and result in tumor reduction.

But also CRCs without MSI or POLE mutations show multiple genetic alterations. These immunogenic mutations, TAAs or neoantigens, need to be identified for vaccine development. Modern next-generation sequencing approaches open up the possibility of easy and fast sequencing but challenges in form of tumor heterogeneity are still to be accomplished. The whole mutational profile of a tumor is difficult to be depicted and for individualized vaccine development, it has to be considered that tumor sequencing can reveal only mutations of a subset of cells and at the time point of operation. The mutational profile of residual metastatic cells might differ\[[@B73],[@B74]\].

One promising approach is to focus on driver mutations that are responsible for maintenance of the transformed status and/or the progression of the individual tumor. Aiming at driver mutations is of advantage in comparison to passenger mutations, as the tumor cell's survival is dependent on these dysregulated gene products and therefore, immune escape by switching off or reverting such mutations is less likely to occur.

The concept of personalized peptide vaccination follows another approach. CRC patients are screened for the presence of CTLs and IgGs against known TAAs and neoantigens in addition to the determination of their HLA profile. Having the knowledge of the patients' HLA layout as well as the natural immunogenicity of the tumor, the vaccine can be adapted by choosing matching peptides for vaccination. This lowers the risk of SAEs by only enhancing the existing antitumoral immune response.

VACCINE DESIGN
==============

When a promising target is found, the design of the vaccine starts. As mentioned before, suiting (better ideal) peptides as well as adjuvants and administration schedules need to be selected. Due to space restrictions, we focus here on peptide-based vaccination strategies and omit recombinant protein- and tumor lysate-based ones.

Single peptides, peptide-loaded antigen-presenting cells or ex vivo expanded T cells?
-------------------------------------------------------------------------------------

Peptides used for vaccination can vary in length. When they directly bind into the peptide-binding groove of the HLA molecules, 8-10-mers (HLA-A/-B/-C) or 13-18-mers (HLA-DP/-DQ/-DR) are typically used. But the binding affinities of peptides to different HLA isoforms deviate. In addition, as the patient is restricted to its individual set of HLA alleles, the efficiency of a peptide vaccine is dependent on the selection of peptides and their best matching HLA. Furthermore, most of the current studies have only investigated peptides restricted to the most common HLA alleles HLA-A2 or HLA-A24, thereby limiting the number of patients benefitting from this therapy.

To circumvent HLA restriction, longer peptides (15-30-mer), so called synthetic long peptides, can be used as these peptides are internalized, processed and presented by antigen presenting cells. The risk of digestion by proteases is also decreased as long peptides form a tertiary structure and have therefore a longer half-life\[[@B75],[@B76]\].

Alternatively, using (autologous) cellular vaccine strategies, completely evades the problem of HLA-restriction and peptide degradation. They can be composed of antigen presenting cells (DCs, B cells or artificial antigen presenting cells\[[@B77]\]) which present the selected peptide(s) to both CD4^+^ helper as well as CD8^+^ effector T cells or the direct approach of applying T cells carrying tumor-antigen-specific T cell receptor(s). For the latter approach, patient specific T cells need to be isolated, expanded and stimulated *in vitro*. After this complex *ex vivo* procedure, a defined amount of functional T cells can be given back to the patient. By including also T helper cells or peptides activating T helper cells, a humoral immune response can be induced, too\[[@B14]\].

Adjuvants
---------

To further enhance the strength of a vaccine, formulations typically include also adjuvants. Incomplete Freund's adjuvant, alum, gold or nanoparticles as well as heat shock proteins and GM-CSF are such adjuvants which improve antigen stability, delivery, processing and presentation to T cells\[[@B78],[@B79]\]. This is achieved by forming a depot at the injection site resulting in slow and prolonged peptide release and/or by induction of proliferation and migration of antigen presenting cells. GM-CSF, as well as TNF receptor ligands and TLR agonists like CpG oligonucleotides, additionally aim at enhancing costimulatory signals for T cell activation. Furthermore, cytokines like interferons or interleukins lead to enhanced immune response in different clinical trials\[[@B80],[@B81]\].

ADVERSE EVENTS
==============

Cancer vaccines are characterized by a high safety and low toxicity profile. Different studies evaluated SAEs grade III/IV after cancer vaccine therapy in around 5500 cancer patients and observed a frequency of \< 3%\[[@B82],[@B83]\]. But especially by using vaccination approaches with TAAs, the possibility of damaging healthy tissue should not be neglected. As mentioned above, TAAs are not restricted to the tumor tissue but only expressed at higher levels compared to (some) normal cells.

In a study with engineered anti-CEA T cells, the CEA levels decreased and even tumor regression was seen in one patient; but all treated patients experienced severe transient inflammatory colitis\[[@B84]\]. The treatment with autologous anti-MAGE-A3/A9/A12 engineered T cells led in another clinical trial to severe neurological toxicity in 3 out of 9 cancer patients\[[@B85]\]. Recognition of different MAGE-A proteins in normal human brain by engineered T cells caused even treatment related mortality in 2 patients. Similarly, the use of engineered T cells showing off-target effects by recognizing un-targeted proteins is associated with an increased risk of SAEs. Linette et al. used an affinity-enhanced T cell receptor against MAGE-A3 and the first two treated patients developed a cardiogenic shock and died within a few days\[[@B86]\]. Recognition of the striated muscle-specific protein titin by these T cells led to severe cardiogenic damage.

As neoantigens are not presented by healthy cells, the risk of SAEs is decreased by using neoantigen-targeting vaccines. To date, vaccine studies focusing on neoantigens in CRC patients observed no SAEs; only mild side effects that resolved spontaneously have been described (*e.g.*, injections site reactions, fever)\[[@B52],[@B62],[@B64],[@B66]\].

CANCER VACCINES: THE SOLUTION TO IMMUNE EVASION?
================================================

The tumor microenvironment is characterized by immunosuppressive signals leading to immune evasion of the tumor. An accumulation of regulatory T cells is responsible for the downregulation of other infiltrating and tumor attacking T cells in an antigen-dependent manner or by secretion of IL-10 or TGF-β\[[@B87]\]. Furthermore, these signal molecules are able to suppress the maturation of DCs resulting in reduced antigen presentation\[[@B88]\]. Tumor-associated macrophages as well as myeloid suppressor cells are also present in the tumor microenvironment and act as immune suppressors\[[@B87],[@B89]\].

But in addition to creating an inhospitable environment for tumor attacking immune cells, tumor cells can also hide from immune cells by modifying their surface to escape recognition. More than 50 % of MSI^high^ CRC patients' tumor harbor mutations that lower the functionality of HLA presentation of antigens\[[@B90]\]: mutations regarding regulation of HLA expression (*e.g*., NLRC5 mutation\[[@B90]\]), peptide transport (*e.g*., TAP1/2 and tapasin\[[@B90]-[@B92]\]) as well as HLA itself (*e.g*., heavy chain\[[@B90]\] and B2M mutation\[[@B91]-[@B93]\]). To overcome this dissembling mechanism, the use of specific chemotherapeutics can be helpful, leading to an effective antitumor immune response by apoptosis (discussed below).

Furthermore, cancer cells take advantage of the control mechanism of nonsense mediated RNA-decay (NMRD). This system is responsible for degrading mRNA with premature stop codons and it has been suggested that this must inhibit the presentation of neoantigens\[[@B94]\]. However, it could be shown that only a part of the so far identified neoantigens are sensitive to NMRD\[[@B51]\].

Last but not least, cancer cells can not only influence cells of the microenvironment to express immune checkpoint molecules but they frequently express such molecules themselves to downregulate T cell activity. Immune checkpoint inhibitors are a precious device in overcoming this tumor-induced immune suppression.

IMMUNE CHECK POINT INHIBITORS
=============================

The field of studies exploring immune checkpoint inhibitors is growing. Targeted immune checkpoints like CTLA-4, PD-1, PD-L1 and LAG-3 are highly expressed in MSI^high^ tumors, thereby creating an immune suppressive microenvironment\[[@B95]\]. Besides, T cells infiltrating in MSI^high^ tumors frequently express PD-L1 making a PD-1 blocking antibody (*e.g*., Pembrolizumab) a helpful instrument\[[@B96]\]: In clinical trials, almost 80 % of MSI high CRC patients benefitted from PD-1 blockade whereas microsatellite stable (MSS) CRC patients rarely did\[[@B96],[@B97]\]. This can be explained by the difference in mutational burden of MSI^high^ and MSS patients, as a correlation of mutational burden/number of neoantigens and clinical response could be proven already\[[@B98],[@B99]\]. Moreover, this clinical observation suggests that a substantial part of these antitumoral immune responses must be HLA-unrestricted, since more than the expected 50% of MSI^high^ patients with functional HLA-presentation responded well. The interplay of adaptive (antitumoral) immune cells with cells of the innate arm of the immune system might partly explain this somewhat surprising finding. Consequently, this would also imply that modern neoantigen-specific vaccines (Figure [2](#F2){ref-type="fig"}) have a good chance to be beneficial for patients with hypermutated tumors despite the fact that HLA-presentation is corrupted due to immune escape phenomena.

![Workflow: preparation of individualized vaccine (using neoantigen targets). The figure shows the possible work flow for individualized cancer vaccination. The colorectal cancer patient (tumor in pink) undergoes tumor resection surgery and biomaterial (tumor (red container) and matching normal (beige container) tissue) is collected. Next generation sequencing and comparative bioinformatics analysis of these biomaterials reveal (tumor-specific) neoantigens and selected peptides are synthesized under GMP conditions. The vaccine consists of synthesized peptides, peptide-loaded antigen-presenting cells, *ex vivo* expanded T cells or chimeric antigen receptor T cells and can be combined with adjuvants, immunogenic chemotherapeutics and/or immune checkpoint inhibitors to further enhance vaccine efficacy. The patient will receive first vaccine shots ideally even before chemotherapeutic intervention. Residual tumor cells (in the colon or circulating as well as micrometastases in other organs) should be eliminated hereby. Exact vaccination scheme will depend on vaccine type, medical facility, *etc*.](WJG-24-5418-g002){#F2}

Studies comparing infiltrating lymphocytes in MSS and MSI^high^ CRC patients revealed, that the amount of infiltrating cells is clearly higher in MSI^high^ tumors, but the correlation between infiltrating lymphocytes and overall survival is only in MSS patients significant\[[@B100],[@B101]\]. Therefore, a combined immunotherapy with blocking immune checkpoints on the one hand and stimulating the immune system with a peptide vaccine on the other hand could help MSS as well as MSI^high^ CRC patients. A first animal study demonstrated increased cytolysis rate, tumor suppression and survival with a DNA vaccine consisting of PD-1 fused with survivin and MUC-1 peptides\[[@B102]\]. Clinical trials investigating the effect of immune checkpoint inhibitors with other forms of immunotherapy in CRC patients are still ongoing (Table [2](#T2){ref-type="table"}).

###### 

Current clinical vaccination studies including colorectal cancer patients

  **Target type**                              **Target molecule**                                 **Vaccination strategy**                                                                                            **Therapy**                                                                                                                        **Number of patients**   **Trial identifier**
  -------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ------------------------ ----------------------
  TAA                                          CEA                                                 alphavirus replicon (VRP) encoding CEA                                                                                                                                                                                                                 12                       NCT01890213
  TAA                                          CEA                                                 ETBX-011 ad-CEA, ALT-803 (IL-15)                                                                                                                                                                                                                       3                        NCT03127098
  TAA                                          CEA                                                 anti-CEA CAR-T cells                                                                                                                                                                                                                                   18                       NCT03682744
  TAA                                          CEA                                                 anti-CEA CAR-T cells                                                                                                                                                                                                                                   5                        NCT02850536
  TAA                                          CEA                                                 anti-CEA CAR-T cells, SIR-Sphere                                                                                                                                                                                                                       8                        NCT02416466
  TAA                                          Her2                                                2 Her2 peptides in Montanide ISA 720                                                                                                                                                                                                                   36                       NCT01376505
  TAA                                          Her2/neu                                            B-Cell and monocytes with HER2/neu antigen                                                                                                                                                                                                             9                        NCT03425773
  TAA                                          Brachyury, CEA, MUC1                                ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-011; adenoviral CEA vaccine                                                                                                                                            32                       NCT03384316
  TAA                                          7 cancer testis antigens                            6 synthetic peptides in Montanide                                                                                   Standard-of care maintenance                                                                                                       15                       NCT03391232
  Immune stimulation, TAA                      MUC1                                                activated CIK and CD3-MUC1 bispecific antibody                                                                      cryotherapy                                                                                                                        90                       NCT03524274
  TAA                                          HPV                                                 DPX-E7                                                                                                                                                                                                                                                 44                       NCT02865135
  TAA                                          hTERT                                               INO-1400 or INO-1401 alone or in combination with INO-9012                                                                                                                                                                                             93                       NCT02960594
  TAA                                          MUC1                                                anti-MUC1 CAR-pNK cells                                                                                                                                                                                                                                10                       NCT02839954
  TAA                                          MUC1                                                MUC1 peptide-poly-ICLC                                                                                                                                                                                                                                 110                      NCT02134925
  TAA                                          EpCAM                                               CAR T Cells targeting EpCAM                                                                                                                                                                                                                            60                       NCT03013712
  Immune checkpoint, TAA                       PD-1, p53                                           Pembrolizumab, modified vaccinia virus Ankara vaccine expressing p53                                                                                                                                                                                   19                       NCT02432963
  Neoantigen                                                                                       frameshift-derived neoantigen-loaded DC                                                                                                                                                                                                                25                       NCT01885702
  Neoantigen                                                                                       personalized neoepitope yeast-based vaccine, YE-NEO-001                                                                                                                                                                                                16                       NCT03552718
  Neoantigen                                                                                       mRNA-based vaccine targeting neoantigens                                                                                                                                                                                                               64                       NCT03480152
  Neoantigen                                                                                       ADXS-NEO (Advaxis NEO expressing personalized tumor antigens)                                                                                                                                                                                          48                       NCT03265080
  Neoantigen                                   ras                                                 anti-KRAS G12 V mTCR                                                                                                Cyclophosphamide, Fludarabine, Aldesleukin                                                                                         110                      NCT03190941
  Immune checkpoint                            PD-L1                                               Avelumab, autologous dendritic cells                                                                                                                                                                                                                   33                       NCT03152565
  Immune checkpoint                            PD-1                                                Pembrolizumab, GVAX (allogeneic colon cancer GM-CSF secreting cells)                                                Cyclophosphamide                                                                                                                   17                       NCT02981524
  Immune checkpoint                            PD-L1                                               Atezolizumab, Imprime PGG (PAMP recognized by innate immune effector cells)                                         Regorafenib/ Isatuximab/ Bevacizumab                                                                                               120                      NCT03555149
  Immune checkpoint                            A2aR, A2bR                                          AB928 (A2aR and A2bR antagonist)                                                                                    FOLFOX                                                                                                                             98                       NCT03720678
  Immune checkpoint, TAA                       PD-1, CEA, MUC-1                                    Nivolumab, MVA-BN-CV301 (modified vaccinia Ankara-Bavarian Nordic encoding CEA, MUC1, B7-1, ICAM-1 and LFA-3)       FOLFOX                                                                                                                             78                       NCT03547999
  Immune checkpoint, TAA                       PD-L1                                               Atezolizumab, RO7198457 (mRNA-based individualized, TAAs vaccine)                                                                                                                                                                                      567                      NCT03289962
  Immune checkpoint, TAA                       PD-L1, CEA                                          Avelumab + Ad-CEA                                                                                                   FOLFOX, Bevacizumab, Capecitabine                                                                                                  81                       NCT03050814
  Immune checkpoint, TAA, Immune stimulation   CEA, Her2/neu, Brachyury, MUC1, RAS, NK cells ICI   Aldoxorubicin, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, HCI, ALT-803      Capecitabine, Cetuximab, Cyclophosphamide, Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT, Trastuzumab   332                      NCT03563157
  Immune checkpoint, Mutated proteins          PD-1                                                Personalized peptides, Pembrolizumab                                                                                                                                                                                                                   60                       NCT02600949
  Immune stimulation                                                                               GVAX (allogeneic colon cancer GM-CSF secreting cells)                                                               Cyclophosphamide, SGI-110 (DNA Methyltransferase Inhibitor)                                                                        18                       NCT01966289
  Immune stimulation                                                                               GVAX (allogeneic colon cancer GM-CSF secreting cells)                                                                                                                                                                                                  15                       NCT01952730
  Immune stimulation                                                                               OncoVAX (non-dividing tumor cells)                                                                                  Surgery                                                                                                                            550                      NCT02448173
  Immune stimulation                                                                               Autologous or allogeneic immune stimulatory tumor cells                                                                                                                                                                                                50                       NCT00722228
  Immune stimulation                                                                               autologous dendritic cells loaded with autologous tumour homogenate + IL-2                                                                                                                                                                             19                       NCT02919644
  Immune stimulation                                                                               autologous dendritic cells loaded with tumor antigens                                                                                                                                                                                                  58                       NCT01348256
  Immune stimulation                                                                               autologous dendritic cells loaded with tumor lysate antigens                                                                                                                                                                                           30                       NCT03214939
  Oncolytic virus                                                                                  GL-ONC1 oncolytic vaccinia virus, which disrupts nonessential genes and expression of the foreign gene expression                                                                                                                                      36                       NCT02714374
  Oncolytic virus, Immune checkpoint           PD-L1                                               Talimogene Laherparepvec, Atezolizumab                                                                                                                                                                                                                 36                       NCT03256344

CEA: Carcinoembryonic antigen; GM-CSF: Granulocyte macrophage colony-stimulating factor; TAA: Tumor-associated antigen.

CANCER VACCINES AND IMMUNOGENIC CELL DEATH
==========================================

The dogma that chemotherapy is immunosuppressive has been disproved. Contrarily, it could be shown that selected chemotherapeutics are able to induce a special kind of cell death which improves tumor immune recognition. This so called immunogenic cell death is characterized by damage-associated molecular patterns on the surface of the tumor cell (calreticulin and heat shock proteins) which are "eat me" signals for immune cells and act as co-stimulators\[[@B103]\]. Inducers of immunogenic cell death are anthracyclines like doxorubicin\[[@B104]\], DNA alkylating cyclophosphamide\[[@B105]\] as well as the common platinum derivative for CRC treatment, oxaliplatin\[[@B106]\]. The studies combining TAAs with different chemotherapeutic agents also observed no immune suppressive effects but induction of specific immune responses\[[@B29],[@B35],[@B36]\]. Therefore, the combination of immunogenic cell death inducing chemotherapeutics and cancer-specific vaccination is an auspicious approach for future treatment of CRC patients (Figure [2](#F2){ref-type="fig"}).

Immunogenic cell death can also be induced by oncolytic viruses which preferentially infect cancer cells. *In vitro* studies revealed that viral treatment can lead to killing of CRC cells, especially tumor initiating cells or cancer stem cells\[[@B107],[@B108]\]. First clinical studies with a combination of oncolytic viruses and immune checkpoint inhibitors in melanoma patients showed response rates up to 62 %\[[@B109]-[@B111]\]. These promising combinations are currently investigated in clinical trials also including CRC patients (Table [2](#T2){ref-type="table"}).

CONCLUSION
==========

Cancer vaccines are a promising instrument for treatment of cancers. The development started with peptides derived from TAAs. These targets can be detected easily and are shared by many patients. Therefore, a variety of studies investigated the effect of TAA-derived peptide vaccines with mediocre results. Low immunogenicity, HLA restriction as well as increased risk of SAEs limit the efficiency and clinical usefulness of this vaccine type.

These problems can likely be solved with novel vaccination approaches focusing on TSAs, mainly neoantigens. They clearly differ from proteins of healthy cells and thus neither self-tolerance nor SAEs are likely to limit clinical application of TSA-based vaccines (see Figure [1](#F1){ref-type="fig"}). First *in vitro* and *in vivo* studies revealed promising results. It can be envisioned that these advantages will on the longer run compensate for the time and money intense identification of patient-individual neoantigens and peptide composition. Pure peptide vaccines, peptide-loaded antigen presenting cells or adoptively transferred T cells will be exploited.

To further enhance the effect of neoantigen vaccines, adjuvants will be included. These improve peptide stability and also act as immune stimulators. Besides, the combination of these new generation individual cancer vaccines with immune checkpoint inhibitors and/or immunogenic cell death-inducing chemotherapeutic agents is an utterly promising concept that will be extensively investigated in the near future. Such multifactorial approaches even have the potential to solve the difficulties in targeting MSS CRC. However, concepts to select the best-suited combinations of vaccines, adjuvants and chemotherapeutic on a patient-individual basis still have to be developed and - possibly even more ambitious - adapted to the clinical routine.
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